These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
385 related items for PubMed ID: 12360485
1. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485 [Abstract] [Full Text] [Related]
2. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2-/- mice and human primary sclerosing cholangitis. Meng F, Kennedy L, Hargrove L, Demieville J, Jones H, Madeka T, Karstens A, Chappell K, Alpini G, Sybenga A, Invernizzi P, Bernuzzi F, DeMorrow S, Francis H. Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751 [Abstract] [Full Text] [Related]
3. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice. Cai SY, Mennone A, Soroka CJ, Boyer JL. J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652 [Abstract] [Full Text] [Related]
5. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. Gastroenterology; 2003 Sep; 125(3):825-38. PubMed ID: 12949728 [Abstract] [Full Text] [Related]
8. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600 [Abstract] [Full Text] [Related]
10. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation. Sokolovic D, Nikolic J, Kocic G, Jevtovic-Stoimenov T, Veljkovic A, Stojanovic M, Stanojkovic Z, Sokolovic DM, Jelic M. Drug Chem Toxicol; 2013 Apr; 36(2):141-8. PubMed ID: 22385135 [Abstract] [Full Text] [Related]
11. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2kd/kd Mice. Hatano R, Kawaguchi K, Togashi F, Sugata M, Masuda S, Asano S. Biol Pharm Bull; 2017 Apr; 40(1):34-42. PubMed ID: 28049946 [Abstract] [Full Text] [Related]
12. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Trauner M, Fickert P, Halilbasic E, Moustafa T. Wien Med Wochenschr; 2008 Apr; 158(19-20):542-8. PubMed ID: 18998069 [Abstract] [Full Text] [Related]
13. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Purucker E, Marschall HU, Winograd R, Matern S. Biochim Biophys Acta; 2001 Apr 03; 1526(1):44-52. PubMed ID: 11287121 [Abstract] [Full Text] [Related]
14. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. J Hepatol; 1996 Mar 03; 24(3):343-52. PubMed ID: 8778203 [Abstract] [Full Text] [Related]
15. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ. Gastroenterology; 1996 Jul 03; 111(1):165-71. PubMed ID: 8698195 [Abstract] [Full Text] [Related]
16. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Denk GU, Maitz S, Wimmer R, Rust C, Invernizzi P, Ferdinandusse S, Kulik W, Fuchsbichler A, Fickert P, Trauner M, Hofmann AF, Beuers U. Hepatology; 2010 Nov 03; 52(5):1758-68. PubMed ID: 21038414 [Abstract] [Full Text] [Related]
17. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis via immunomodulatory effects. Fuchs CD, Dixon ED, Hendrikx T, Mlitz V, Wahlström A, Ståhlman M, Scharnagl H, Stojakovic T, Binder CJ, Marschall HU, Trauner M. Hepatol Commun; 2022 Sep 03; 6(9):2368-2378. PubMed ID: 35691019 [Abstract] [Full Text] [Related]
18. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis. Gao RY, Shearn CT, Orlicky DJ, Battista KD, Alexeev EE, Cartwright IM, Lanis JM, Kostelecky RE, Ju C, Colgan SP, Fennimore BP. Mucosal Immunol; 2021 Mar 03; 14(2):479-490. PubMed ID: 33004979 [Abstract] [Full Text] [Related]
19. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Gastroenterology; 2001 Jul 03; 121(1):170-83. PubMed ID: 11438506 [Abstract] [Full Text] [Related]
20. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. Macias RI, Serrano MA, Monte MJ, Jimenez S, Hernandez B, Marin JJ. J Pharmacol Exp Ther; 2005 Feb 03; 312(2):751-8. PubMed ID: 15452192 [Abstract] [Full Text] [Related] Page: [Next] [New Search]